StockNews.com assumed coverage on shares of Trinity Biotech (NASDAQ:TRIB – Get Rating) in a research note issued to investors on Friday morning. The firm issued a buy rating on the stock.
Separately, TheStreet downgraded Trinity Biotech from a c- rating to a d rating in a research report on Tuesday, July 5th.
Get
Trinity Biotech alerts:
Trinity Biotech Price Performance
Shares of TRIB opened at $1.19 on Friday. Trinity Biotech has a 1 year low of $0.86 and a 1 year high of $3.05. The company has a market capitalization of $32.03 million, a price-to-earnings ratio of -2.33 and a beta of 1.33. The business has a 50-day moving average of $1.35 and a 200-day moving average of $1.22.
Trinity Biotech (NASDAQ:TRIB – Get Rating) last issued its quarterly earnings data on Thursday, June 30th. The company reported ($0.08) earnings per share (EPS) for the quarter. Trinity Biotech had a negative return on equity of 347.92% and a negative net
margin of 15.10%. The company had revenue of $18.78 million for the quarter.
Institutional Investors Weigh In On Trinity Biotech
Hedge funds have recently added to or reduced their stakes in the business. Atria Wealth Solutions Inc. bought a new stake in Trinity Biotech in the first quarter worth approximately $27,000. Whitefort Capital Management LP acquired a new stake in Trinity Biotech in the fourth quarter valued at approximately $50,000. Virtu Financial LLC acquired a new stake in Trinity Biotech in the first quarter valued at approximately $40,000. Envestnet Asset Management Inc. acquired a new stake in Trinity Biotech in the fourth quarter valued at approximately $159,000. Finally, Highbridge Capital Management LLC acquired a new stake in Trinity Biotech in the first quarter valued at approximately $1,221,000. 27.11% of the stock is currently owned by institutional investors.
Trinity Biotech Company Profile
(Get Rating)
Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.
Recommended Stories
- Get a free copy of the StockNews.com research report on Trinity Biotech (TRIB)
- Could Snap Stock Rebound As Management Restructures?
- MarketBeat: Week in Review 8/29 – 9/2
- Hormel Looks Cheap At These Levels
- Lululemon Set To Soar Into September
- Could Nike Stock be Oversold, but Still Overvalued?
Receive News & Ratings for Trinity Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
